Category Archives: TRIPS flexibilities

Malaysian CL on Hep C drug reignites discussion in India

Source: The Hindu BusinessLine MUMBAI, OCTOBER 9:   Last month, Malaysia issued a compulsory licence (CL) on multinational drugmaker Gilead’s Hepatitis C drug Sofosbuvir for government use. This government action aimed at improving access to the drug in Malaysia has in fact … Continue reading

Posted in Compulsory Licensing, Hepatitis C, TRIPS flexibilities, Uncategorized | Leave a comment

US needs to push range of economic issues with India: Kenneth Juster

Source: The Economic Times WASHINGTON: The US must push a range of economic issues with India, including intellectual property, standard and non-tariff barriers, President Donald Trump’s nominee to be the next envoy to India has told lawmakers. Underlining that there … Continue reading

Posted in Compulsory Licensing, IPR, Uncategorized | Leave a comment

DNDi welcomes Malaysia’s move to secure access to more affordable treatments for hepatitis C

[Kuala Lumpur, Geneva – 20 September 2017] Malaysia has issued a “government use” licence enabling access to more affordable versions of an expensive and patented medicine to treat hepatitis C. This landmark decision should help the more than 400,000 people living with … Continue reading

Posted in Compulsory Licensing, Hepatitis C, Uncategorized | Leave a comment

Seven Decades of Grappling With Intellectual Property Issues in India

Create, Copy, Disrupt: India’s Intellectual Property Dilemmas is well-researched and easy to read, especially for a non-legal audience. By Jayashree Watal, The Wire The book Create, Copy, Disrupt: India’s Intellectual Property Dilemmas (OUP, 2017) is a serious effort by two legal scholars, Prashant … Continue reading

Posted in IPR, TRIPS, TRIPS flexibilities, TRIPS plus, TRIPS&IP rights, Uncategorized | Leave a comment

South African IP policy draft released seeking comments from public

International Trade and Economic Development division of South African Government has released the  Draft Intellectual Property Policy of the Republic of south Africa Phase 2017 and it is now publicly available for comments.  Access the draft policy here: http://www.dti.gov.za/gazzettes/IP_Policy.pdf   

Posted in IPR, R&D, TRIPS, TRIPS flexibilities, TRIPS plus, Uncategorized | Leave a comment

No logic in extending length of patents

Granting a longer term for pharmaceutical patents will result in delays in the entry of generic versions and could adversely affect access to medicines   By Feroz Ali, Live Mint | July 28, 2017 A proposal to further extend the … Continue reading

Posted in Biologics/Biosimilars, Data Exclusivity, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, TRIPS, TRIPS flexibilities, TRIPS plus, TRIPS&IP rights, Uncategorized | Leave a comment

An Access Regime based on Indian Patents Act -Review Of “The Access Regime” by Feroz Ali

Source: LiveLaw.in Even though the Agreement on the trade-related aspects of intellectual property rights (TRIPS) set the minimum standards of protection and enforcement of intellectual property (IP) rights, it could not harmonise the various national patent laws. Irrespective of the … Continue reading

Posted in Compulsory Licensing, FTA, Patent Opposition, Sec 3 (d), TRIPS, TRIPS flexibilities, TRIPS plus, Uncategorized | Leave a comment